

Title (en)

INTRANASAL DELIVERY OF PNEUMOCOCCAL POLYSACCHARIDE VACCINES

Title (de)

INTRANASALE VERABREICHUNG VON PNEUMOKOKKEN-POLYSACCHARID-IMPFSTOFFEN

Title (fr)

ADMINISTRATION INTRANASALE DE VACCINS A POLYSACCHARIDES PNEUMOCOCCIQUES

Publication

**EP 1161259 A1 20011212 (EN)**

Application

**EP 00920613 A 20000310**

Priority

- EP 00920613 A 20000310
- EP 0002749 W 20000310
- EP 99104803 A 19990311

Abstract (en)

[origin: EP1034792A1] The invention relates to a method for preventing against diseases induced by *Streptococcus pneumoniae* infections, which comprises mucosally administering to a patient in need a *S. pneumoniae* capsular polysaccharide. This latter may be conjugated or not and is preferably mixed with a mucosal adjuvant such as cholera toxin, *E. coli* heat-labile toxin or Rhinovax TM . A preferred route of administration is the intranasal route.

IPC 1-7

**A61K 39/09; A61K 39/385; A61K 39/39; A61P 31/04**

IPC 8 full level

**A61K 39/05** (2006.01); **A61K 39/08** (2006.01); **A61K 39/106** (2006.01); **A61K 39/108** (2006.01); **A61K 39/09** (2006.01); **A61K 39/385** (2006.01);  
**A61K 39/39** (2006.01); **A61K 47/48** (2006.01); **A61P 11/00** (2006.01); **A61P 31/04** (2006.01)

CPC (source: EP US)

**A61K 39/092** (2013.01 - EP US); **A61K 47/646** (2017.08 - EP US); **A61P 11/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP);  
**A61K 2039/543** (2013.01 - EP US); **A61K 2039/55566** (2013.01 - EP US); **A61K 2039/6037** (2013.01 - EP US)

Citation (examination)

- SUN K. ET AL: "An important role for polymeric Ig receptor-mediated transport of IgA in protection against *Streptococcus pneumoniae* nasopharyngeal carriage.", J. IMMUNOL., vol. 173, 2004, pages 4576 - 4581
- Retrieved from the Internet <URL:<http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=4428>>
- MCGHEE J.R. ET AL: "The mucosal immune system : from fundamental concepts to vaccine development.", VACCINE, vol. 10, no. 2, 1992, pages 75 - 88
- LYNCH J.M. ET AL: "Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.", INFECT. IMMUN., vol. 71, no. 8, August 2003 (2003-08-01), pages 4780 - 4788
- See also references of WO 0053221A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**EP 1034792 A1 20000913**; AU 4113000 A 20000928; AU 779698 B2 20050210; CA 2364442 A1 20000914; EP 1161259 A1 20011212;  
HU P0200405 A2 20020629; JP 2003527309 A 20030916; NO 20014326 D0 20010905; NO 20014326 L 20011102; NZ 514089 A 20010928;  
US 2002094338 A1 20020718; US 2006140981 A1 20060629; WO 0053221 A1 20000914

DOCDB simple family (application)

**EP 99104803 A 19990311**; AU 4113000 A 20000310; CA 2364442 A 20000310; EP 0002749 W 20000310; EP 00920613 A 20000310;  
HU P0200405 A 20000310; JP 2000603710 A 20000310; NO 20014326 A 20010905; NZ 51408900 A 20000310; US 35802106 A 20060221;  
US 95014601 A 20010910